Olsen, Mikkel Thor
Klarskov, Carina Kirstine
Pedersen-Bjergaard, Ulrik
Hansen, Katrine Bagge
Kristensen, Peter Lommer
Funding for this research was provided by:
Vissing Fonden (512194 AHO/LAX, 512194 AHO/LAX, 512194 AHO/LAX)
Jascha Fonden (2022-0294, 2022-0294, 2022-0294)
Copenhagen University Hospital North Zealand Research Grant
Fru Olga Bryde Nielsen Fonden
PhD-START-puljen North Zealand Hospital
A.P. Møller Fonden til Lægevidenskabens Fremme
A & J C Tvergaards Fond
Læge Inger Goldmanns Fond
Torben og Alice Frimodts Fond
Ellen Cramers Fond
Article History
Received: 25 July 2023
Accepted: 30 April 2024
First Online: 6 May 2024
Declarations
:
: The DAITEC trial follows the Declaration of Helsinki, the ISO 14155 standard, and regulations by the Medical Research Ethics Committees (approved v. 1.2 clinical investigation plan on 10<sup>th</sup> March 2023 with number 2301240 and by the Data Protection Agency the 2<sup>nd</sup> January 2023 with number P-2022-988). The Qualification for authorship follows the Vancouver recommendations. Amendments will be described in future publications. Informed written consent is obtained by investigators from all patients before enrollment by a standardised consent form (S2, August, 2016) from the Medical Research Ethics Committees.
: Not applicable.
: MTO: None; CK: None; UPB: Has received speakers fee from Sanofi and Novo Nordisk and has served on advisory boards for Sanofi, Novo Nordisk, and Vertex; KBH: None; PLK: Has received speakers fee from Sanofi, Novo Nordisk, Boehringer Ingelheim, and AstraZeneca.